Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment
Abdominal Radiology · 2025
DOI: 10.1007/s00261-025-05215-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2025. Verfasst von Sara Hassanzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Glucagon, Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
PURPOSE: To evaluate the effectiveness of subcutaneous glucagon in reducing motion artifact during prostate MRI through intraindividual comparison. METHODS: At our institution patients undergoing a clinical prostate MRI exam receive 1 mg of subcutaneous glucagon before scanning. From February 15, 2024 to February 11, 2025 33 such patients were recruited to undergo an additional, research exam without glucagon. All exams were acquired at 3T. An axial T2-weighted spin-echo series (T2-WI) was acquired within both exams. Evaluation of the T2-WI series was done by three experienced radiologists using the criteria of diagnostic quality (0-3 scale), PI-QUALv2 (0-3 sum), motion artifact (significant, visible, none), and reviewer preference (five-point relative scale). Due to differences in prescribed coverage, the scan times for the two T2-WI sequences were in general different for each subject. Results were stratified using the acquisition time ratio (Trel) between the glucagon vs. non-glucagon scans. Wilcoxon tests assessed score differences. RESULTS: Across all 33 subjects, no significant differences were found between glucagon and non-glucagon scans. However, the observed negative correlation between glucagon preference and Trel (p = 0.026) led to stratification into low-Trel (N = 16) and high-Trel (N = 17) groups. In the low-Trel group the glucagon scans provided significantly improved diagnostic quality (p = 0.048), PI-QUALv2 sum (p = 0.049), motion scores (p = 0.047), and reader preference (p = 0.042). CONCLUSION: Subcutaneous glucagon provides improved image quality in prostate T2-WI MRI when scan duration remains within 1.25× of that of a non-glucagon T2-WI series. The benefit appears to decrease with longer scan times.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, MN, USA.
- Department of Radiology, Mayo Clinic, Phoenix, AZ, USA.
- Department of Radiology, Mayo Clinic, Rochester, MN, USA. riederer@mayo.edu.
Förderung
- NIBIB NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Hassanzadeh, S., Borisch, E. A., Froemming, A. T., Kawashima, A., Takahashi, N., & Riederer, S. J. (2025). Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment. Abdominal Radiology. https://doi.org/10.1007/s00261-025-05215-0
Vancouver
Hassanzadeh S, Borisch EA, Froemming AT, Kawashima A, Takahashi N, Riederer SJ. Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment. Abdominal Radiology. 2025. doi:10.1007/s00261-025-05215-0
BibTeX
@article{Hassanzadeh2025,
author = {Hassanzadeh, Sara and Borisch, Eric A and Froemming, Adam T and Kawashima, Akira and Takahashi, Naoki and Riederer, Stephen J},
title = {Prostate T2-weighted spin-echo MRI with and without glucagon: a paired scan quality assessment},
journal = {Abdominal Radiology},
year = {2025},
doi = {10.1007/s00261-025-05215-0}
}
EUVIMED